基因型对2019年ARVC风险计算器风险分层的重要性
本研究纳入554例确诊ARVC且无持续性室性心律失常病史的患者,中位随访6.0年,18%发生主要室性心律失常结局,年事件率2.6%。2019年ARVC风险模型区分度尚可但高估风险,区分度和校准度在PKP2组最高、基因未明组最低,基因型应纳入未来风险模型。
要点
- 2019年ARVC风险模型在基因阳性患者中表现较好,尤其PKP2组。
- 基因未明组模型区分度和校准度最低,风险预测受限。
- 不同基因型中临床风险标志物作用不同,如右室指标仅PKP2显著。
核心结论
- 2019年ARVC风险模型在基因阳性ARVC中表现尚可,尤其PKP2组,但在基因未明患者中受限。
- 基因型应纳入未来ARVC风险模型。
研究设计与样本
- 研究队列为554例确诊ARVC且无持续性室性心律失常病史的患者。
- 中位随访6.0(3.1,12.5)年。
主要发现
- 随访期间100例(18%)发生主要室性心律失常结局,年事件率2.6%(95%CI 1.9-3.3)。
- 2019年ARVC风险模型区分度尚可但高估风险。
- 模型区分度和校准度在PKP2组最高,在基因未明组最低。
- 单变量分析显示不同基因组的临床风险标志物表现不同。
关键数值与推荐
- 基因分组:PKP2(n=118,21%)、DSP(n=79,14%)、其他桥粒基因(n=59,11%)、基因未明(n=160,29%)。
临床怎么用
- 使用2019年ARVC风险模型时应考虑基因型,尤其在基因未明患者中谨慎解读风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To study the impact of genotype on the performance of the 2019 risk model for arrhythmogenic right ventricular cardiomyopathy (ARVC). METHODS AND RESULTS: The study cohort comprised 554 patients with a definite diagnosis of ARVC and no history of sustained ventricular arrhythmia (VA). During a median follow-up of 6.0 (3.1,12.5) years, 100 patients (18%) experienced the primary VA outcome (sustained ventricular tachycardia, appropriate implantable cardioverter defibrillator intervention, aborted sudden cardiac arrest, or sudden cardiac death) corresponding to an annual event rate of 2.6% [95% confidence interval (CI) 1.9-3.3]. Risk estimates for VA using the 2019 ARVC risk model showed reasonable discriminative ability but with overestimation of risk. The ARVC risk model was compared in four gene groups: PKP2 (n = 118, 21%); desmoplakin (DSP) (n = 79, 14%); other desmosomal (n = 59, 11%); and gene elusive (n = 160, 29%). Discrimination and calibration were highest for PKP2 and lowest for the gene-elusive group. Univariable analyses revealed the variable performance of individual clinical risk markers in the different gene groups, e.g. right ventricular dimensions and systolic function are significant risk markers in PKP2 but not in DSP patients and the opposite is true for left ventricular systolic function. CONCLUSION: The 2019 ARVC risk model performs reasonably well in gene-positive ARVC (particularly for PKP2) but is more limited in gene-elusive patients. Genotype should be included in future risk models for ARVC.
引用
- Protonotarios A, Bariani R, Cappelletto C, et al. Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. Eur Heart J. 2022. PMID: 35766183. doi:10.1093/eurheartj/ehac235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。